Strive Pharmacy Texas LLC dba Strive Pharmacy

CLOSEOUT LETTER Strive Pharmacy Texas LLC dba Strive Pharmacy MARCS-CMS 639220 — May 13, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT Product: Drugs Recipient: Recipient Name Nathan Hill Recipient Title Chief Executive Officer Strive Pharmacy Texas LLC dba Strive Pharmacy Vita Pharmacy, LLC dba Talon Pharmacy of Boerne 3975 East Mesquite Street Gilbert , AZ 85296 United States Issuing Office: Office of Pharmaceutical Quality Operations, Division II United States Secondary Issuing Offices United States Dear Mr. Hill: The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter #639220, issued on August 29, 2022. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter. You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means. Sincerely, /S/ Matthew J. Lash Acting Director Office of Compounding Quality and Compliance Office of Compliance Center for Drug Evaluation and Research Content current as of: 05/28/2026 Regulated Product(s) Drugs